Zhichao Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3723922/publications.pdf

Version: 2024-02-01

51 papers	1,029 citations	471509 17 h-index	434195 31 g-index
55 all docs	55 docs citations	55 times ranked	1359 citing authors

#	Article	IF	Citations
1	Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis. Biochemical Pharmacology, 2022, 198, 114964.	4.4	8
2	Structure-Based Design and Structure-Activity Relationship Analysis of Small Molecules Inhibiting Bcl-2 Family Members. Pharmaceutical Chemistry Journal, 2022, 56, 329-338.	0.8	1
3	A â€œThreeâ€inâ€Oneâ€•Multifunctional Probe for Bclâ€2/Mclâ€1 Profiling and Visualizing in Situ. ChemBioChem, 2021, 22, 326-329.	2.6	0
4	Small-molecule inhibitor targeting the Hsp70-Bim proteinâ€“protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance. Leukemia, 2021, 35, 2862-2874.	7.2	13
5	Ectopic BH3-only protein Bim acts as a co-chaperone to positively regulate Hsp70 in yeast. Journal of Biochemistry, 2021, 170, 539-545.	1.7	4
6	Discovery of a Fluorogenic Probe for In Situ Pyruvate Kinase M2 Isoform (PKM2) Labeling through Chemoselective S_NAr with a Binding Site Lysine Residue. Analytical Chemistry, 2021, 93, 9669-9676.	6.5	3
7	Structure-Based Optimization of 3-Phenyl-N-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10260-10285.	6.4	6
8	Bim transfer between Bcl-2-like protein and Hsp70 underlines Bcl-2/Hsp70 crosstalk to regulate apoptosis. Biochemical Pharmacology, 2021, 190, 114660.	4.4	14
9	A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction. European Journal of Medicinal Chemistry, 2021, 220, 113452.	5.5	16
10	Identification of the Apoptosis and Autophagy Biâ€functional Proteins. Molecular Informatics, 2020, 39, e1900008.	2.5	0
11	Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1. European Journal of Pharmaceutical Sciences, 2020, 142, 105105.	4.0	7
12	Large-Scale Biomolecular Conformational Transitions Explored by a Combined Elastic Network Model and Enhanced Sampling Molecular Dynamics. Journal of Physical Chemistry Letters, 2020, 11, 325-332.	4.6	11
13	The chaperone Hsp70 is a BH3 receptor activated by the pro-apoptotic Bim to stabilize anti-apoptotic clients. Journal of Biological Chemistry, 2020, 295, 12900-12909.	3.4	20
14	Targeting the Allosteric Pathway That Interconnects the Core-Functional Scaffold and the Distal Phosphorylation Sites for Specific Dephosphorylation of Bcl-2. Journal of Medicinal Chemistry, 2020, 63, 13733-13744.	6.4	4
15	Higher Accuracy Achieved for Proteinâ€“Ligand Binding Pose Prediction by Elastic Network Model-Based Ensemble Docking. Journal of Chemical Information and Modeling, 2020, 60, 2939-2950.	5.4	13
16	Structureâ€based design, synthesis, and evaluation of Bclâ€2/Mclâ€1 dual inhibitors. Archiv Der Pharmazie, 2020, 353, e2000005.	4.1	7
17	Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands. Journal of Medicinal Chemistry, 2019, 62, 8152-8163.	6.4	75
18	Quantitative Lysine Reactivity Profiling Reveals Conformational Inhibition Dynamics and Potency of Aurora A Kinase Inhibitors. Analytical Chemistry, 2019, 91, 13222-13229.	6.5	13

#	Article	IF	Citations
19	A novel turn-on fluorescent probe for selective sensing and imaging of glutathione in live cells and organisms. Analyst, The, 2019, 144, 3260-3266.	3.5	19
20	Highly stable lithiumâ€“sulfur batteries based on pâ€“n heterojunctions embedded on hollow sheath carbon propelling polysulfides conversion. Journal of Materials Chemistry A, 2019, 7, 9230-9240.	10.3	79
21	Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis. Biochemical and Biophysical Research Communications, 2019, 512, 921-926.	2.1	5
22	Systems analysis of phosphorylationâ€regulated Bclâ€2 interactions establishes a model to reconcile the controversy over the significance of Bclâ€2 phosphorylation. British Journal of Pharmacology, 2019, 176, 491-504.	5.4	9
23	Expression and Solution NMR Study of Multi-site Phosphomimetic Mutant BCL-2 Protein. Protein and Peptide Letters, 2019, 26, 449-457.	0.9	1
24	Nanopore-confined g-C₃N₄ nanodots inÂN, S co-doped hollow porous carbon with boosted capacity for lithiumâ€“sulfur batteries. Journal of Materials Chemistry A, 2018, 6, 7133-7141.	10.3	80
25	Higher Accuracy Achieved in the Simulations of Protein Structure Refinement, Protein Folding, and Intrinsically Disordered Proteins Using Polarizable Force Fields. Journal of Physical Chemistry Letters, 2018, 9, 7110-7116.	4.6	24
26	Identification of JNK1 as a predicting biomarker for ABT-199 and paclitaxel combination treatment. Biochemical Pharmacology, 2018, 155, 102-109.	4.4	12
27	Proteomeâ€Wide Identification of Onâ€and Offâ€Targets of Bclâ€2 Inhibitors in Native Biological Systems by Using Affinityâ€Based Probes (AfBPs). ChemBioChem, 2018, 19, 2312-2320.	2.6	11
28	Fragmentâ€Based Design, Synthesis, and Biological Evaluation of 1â€Substitutedâ€indoleâ€2â€carboxylic Acids as Selective Mclâ€1 Inhibitors. Archiv Der Pharmazie, 2017, 350, e1600251.	4.1	14
29	Mechanism of Mclâ€1 Conformational Regulation Upon Small Molecule Binding Revealed by Molecular Dynamic Simulation. Chemical Biology and Drug Design, 2016, 87, 551-561.	3.2	10
30	Bclâ€2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABTâ€737, ABTâ€263 and ABTâ€199 by impeding direct binding. British Journal of Pharmacology, 2016, 173, 471-483.	5.4	49
31	Substituted indole Mcl-1 inhibitors: a patent evaluation (WO2015148854A1). Expert Opinion on Therapeutic Patents, 2016, 26, 1227-1238.	5.0	1
32	Deactivation of Mclâ€1 by Dualâ€Function Smallâ€Molecule Inhibitors Targeting the Bclâ€2 Homology 3 Domain and Facilitating Mclâ€1 Ubiquitination. Angewandte Chemie - International Edition, 2016, 55, 14250-14256.	13.8	35
33	Deactivation of Mclâ€1 by Dualâ€Function Smallâ€Molecule Inhibitors Targeting the Bclâ€2 Homology 3 Domain and Facilitating Mclâ€1 Ubiquitination. Angewandte Chemie, 2016, 128, 14462-14468.	2.0	1
34	Titelbild: Deactivation of Mcl-1 by Dual-Function Small-Molecule Inhibitors Targeting the Bcl-2 Homology 3 Domain and Facilitating Mcl-1 Ubiquitination (Angew. Chem. 46/2016). Angewandte Chemie, 2016, 128, 14387-14387.	2.0	0
35	Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like Î±-Helical Mimetics. Journal of Medicinal Chemistry, 2016, 59, 3152-3162.	6.4	21
36	Caspase-mediated cleavage of Beclin1 inhibits autophagy and promotes apoptosis induced by S1 in human ovarian cancer SKOV3 cells. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 225-238.	4.9	23

#	Article	IF	Citations
37	Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. European Journal of Pharmaceutical Sciences, 2015, 70, 64-71.	4.0	15
38	Novel Mclâ€1/Bclâ€2 Dual Inhibitors Created by the Structureâ€Based Hybridization of Drugâ€Divided Building Blocks and a Fragment Deconstructed from a Known Twoâ€Face BH3 Mimetic. Archiv Der Pharmazie, 2015, 348, 89-99.	4.1	7
39	Discovery of a Smallâ€Molecule pBclâ€2 Inhibitor that Overcomes pBclâ€2â€Mediated Resistance to Apoptosis. ChemBioChem, 2015, 16, 757-765.	2.6	8
40	Design, synthesis and structureâ€“activity relationship studies of morpholino-1H-phenalene derivatives that antagonize Mcl-1/Bcl-2. Bioorganic and Medicinal Chemistry, 2014, 22, 5738-5746.	3.0	6
41	Study of Binding Thermodynamics in the Optimization of <scp>BH</scp>3 Mimetics. Chemical Biology and Drug Design, 2013, 82, 394-400.	3.2	1
42	Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors. European Journal of Medicinal Chemistry, 2013, 60, 410-420.	5.5	24
43	3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1. Bioorganic and Medicinal Chemistry, 2013, 21, 11-20.	3.0	32
44	Design and application of a rigid quinazolone scaffold based on two-face Bim Î±-helix mimicking. European Journal of Medicinal Chemistry, 2013, 69, 711-718.	5.5	8
45	Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach. European Journal of Medicinal Chemistry, 2013, 59, 141-149.	5.5	27
46	An Anthraquinone Scaffold for Putative, Two-Face Bim BH3 Î±-Helix Mimic. Journal of Medicinal Chemistry, 2012, 55, 10735-10741.	6.4	25
47	3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) Based Molecules as Potent, Dual Inhibitors of B-Cell Lymphoma 2 (Bcl-2) and Myeloid Cell Leukemia Sequence 1 (Mcl-1): Structure-Based Design and Structureâ^'Activity Relationship Studies. Journal of Medicinal Chemistry, 2011, 54, 1101-1105.	6.4	76
48	Probing the difference between BH3 groove of Mcl-1 and Bcl-2 protein: Implications for dual inhibitors design. European Journal of Medicinal Chemistry, 2011, 46, 3909-3916.	5.5	29
49	A novel BH3 mimetic S1 potently induces Bax/Bakâ€dependent apoptosis by targeting both Bclâ€2 and Mclâ€1. International Journal of Cancer, 2011, 128, 1724-1735.	5.1	67
50	Inclusion Complex of a Bcl-2 Inhibitor with Cyclodextrin: Characterization, Cellular Accumulation, and in Vivo Antitumor Activity. Molecular Pharmaceutics, 2010, 7, 1348-1354.	4.6	13
51	Novel Bcl-2 Inhibitors: Discovery and Mechanism Study of Small Organic Apoptosis-Inducing Agents. ChemBioChem, 2007, 8, 113-121.	2.6	69